Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects with Relapsed and Refractory Multiple Myeloma

ID Number 15-1200

Principal Investigator(s)
Sundar Jagannath

Department(s) or Division(s)
Hematology and Medical Oncology


ABBV-838 (an investigational drug), which means that it has not yet been approved by the U.S. Food and Drug Administration (FDA).  ABBV-838 is a protein called a monoclonal antibody that is coupled with a chemotherapeutic agent that may target and kill cancer cells, specifically cancerous plasma cells in multiple myeloma directly and help your immune system fight multiple myeloma.  Although laboratory studies have shown that ABBV-838 can kill cancer cells in the laboratory and shrink tumors in laboratory test on animals, we do not know if ABBV-838 will work in patients with multiple myeloma.

Contact Information
Lisa La
(212) 241-8615

Recruiting Patients: Yes